医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Intertek Gains Official Accreditation with Philippine Food and Drug Administration

2015年06月16日 AM10:00
このエントリーをはてなブックマークに追加


 

MAKATI, Philippines

Intertek (LSE: ITRK), a leading provider of quality services to a wide range of industries worldwide, has achieved official accreditation for the testing of various food products, food supplements, beverages, bottled water, human drugs and herbal supplements, cosmetics and toys products, under the Philippine Food and Drug Administration Laboratory Accreditation (FDALA) Scheme.

This official accreditation is an important milestone for Intertek as it further demonstrates the organisation’s dedicated commitment and enhanced competency towards continual product and process improvement. The approved accredited facility located at Makati City, the central financial district of Manila, offers integrated solutions, including established expertise for the food, pharmaceutical and consumer goods industries. Broader analytical capabilities include physico-chemical tests, microbiological assessments, as well as nutritional labelling.

Intertek Food Services supports the food industry from farm to fork, including producers, manufacturers to Food Business Operators (FBOs), with integrated solutions that help customers to identify the relevance quickly and guide them effectively through improved analytical processes, in response to market and regulatory changes.

Ms Sandy Bucao, Country Managing Director of Intertek Philippines said: “Intertek is delighted to have been awarded with the official accreditation by the Philippine FDA, as it complements the existing local capabilities. It fosters an important partnership with the local authorities in promoting food safety and quality and also in limiting the number of non-compliant products in the market.”

The accreditation will provide Intertek customers with much needed assurance as they try to keep up with the growing number of product compliance requirements being implemented by the FDA. The Philippine FDA requires every manufacturer, seller or distributor of food, drugs, beverage, bottled water, cosmetics and toy products to secure a Certificate of Product Registration (CPR) without which their products cannot be allowed to be sold in the Philippines. The CPR requires the submission of Certificate of Analysis (COA) from an accredited laboratory. Likewise, for food products, the role of the accredited labs is important in meeting the new food labeling requirements which will soon be implemented by the FDA.

To learn more about Intertek Food Solutions:

http://www.intertek.com/food/

About Intertek

Intertek is a leading quality solutions provider to industries worldwide. From auditing and inspection, to testing, training, advisory, quality assurance and certification, Intertek adds value for its customers by helping improve the quality and safety of their products, assets and processes. With a network of more than 1,000 laboratories and offices and over 38,000 people in more than 100 countries, Intertek supports companies’ success in the global marketplace, by helping customers to meet end users’ expectations for safety, sustainability, performance, integrity and desirability in virtually any market worldwide.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150615006033/en/

CONTACT

Intertek
Media enquiries:
Adrian Ho, +65 9833 0839
Marketing
Communications Manager (SE Asia)
adrian.ho@intertek.com
Market
enquiries:
Sandy Bucao, +63 28195841/47
Country Managing
Director, Philippines
sandy.bucao@intertek.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease